Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 161

1.

Improving breast cancer sensitivity to paclitaxel by increasing aneuploidy.

Rodrigues-Ferreira S, Nehlig A, Moindjie H, Monchecourt C, Seiler C, Marangoni E, Chateau-Joubert S, Dujaric ME, Servant N, Asselain B, de Cremoux P, Lacroix-Triki M, Arnedos M, Pierga JY, André F, Nahmias C.

Proc Natl Acad Sci U S A. 2019 Nov 19;116(47):23691-23697. doi: 10.1073/pnas.1910824116. Epub 2019 Nov 4.

PMID:
31685623
2.

First French Pilot Quality Assessment of the EndoPredict Test for Early Luminal Breast Carcinoma.

Lehmann-Che J, Miquel C, Wong J, Callens C, Rouleau E, Quillien V, Lozano N, Cayre A, Lacroix L, Bieche I, Bertheau P, Teixeira L, Llorca FP, Lamy PJ, DE Cremoux P; GFCO GROUP.

Anticancer Res. 2018 May;38(5):2909-2914.

PMID:
29715116
3.

18FDG-PET/CT and molecular markers to predict response to neoadjuvant chemotherapy and outcome in HER2-negative advanced luminal breast cancers patients.

de Cremoux P, Biard L, Poirot B, Bertheau P, Teixeira L, Lehmann-Che J, Bouhidel FA, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, Groheux D.

Oncotarget. 2018 Mar 27;9(23):16343-16353. doi: 10.18632/oncotarget.24674. eCollection 2018 Mar 27.

4.

Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.

Groheux D, Biard L, Lehmann-Che J, Teixeira L, Bouhidel FA, Poirot B, Bertheau P, Merlet P, Espié M, Resche-Rigon M, Sotiriou C, de Cremoux P.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(8):1279-1288. doi: 10.1007/s00259-018-3998-z. Epub 2018 Apr 4.

PMID:
29616304
5.

COX2/PTGS2 Expression Is Predictive of Response to Neoadjuvant Celecoxib in HER2-negative Breast Cancer Patients.

DE Cremoux P, Hamy AS, Lehmann-Che J, Scott V, Sigal B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Giacchetti S, Brain E, Marty M, Asselain B, Spyratos F, Bièche I.

Anticancer Res. 2018 Mar;38(3):1485-1490.

PMID:
29491076
6.

Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review.

Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, Fontugne J, Georges A, Hennequin C, Lehmann-Che J, Massard C, Millet I, Murez T, Schlageter MH, Rouvière O, Kassab-Chahmi D, Rozet F, Descotes JL, Rébillard X.

Eur Urol Focus. 2018 Dec;4(6):790-803. doi: 10.1016/j.euf.2017.02.017. Epub 2017 Mar 7.

PMID:
28753865
7.

[Results of the Massive Open Online Course (MOOC) on cancer diagnosis and evaluation of its impact on the perception of the pathology specialty].

Gardair C, Bousquet G, de Bazelaire C, Lehmann-Che J, de Cremoux P, Tran Van Nhieu J, Battistella M, Sockeel M, Calvani J, Peuchmaur M, Molina T, Gervais J, Moenaert E, Pottier Y, Prévaut L, Sekri K, Bertheau P.

Ann Pathol. 2017 Apr;37(2):144-150. doi: 10.1016/j.annpat.2017.02.001. Epub 2017 Mar 17. French.

PMID:
28318775
8.

[A case report of chordoid glioma with unusual features: Immunohistochemical and molecular findings and differential diagnoses].

Tauziède-Espariat A, Robert G, de Cremoux P, Polivka M.

Ann Pathol. 2017 Apr;37(2):151-157. doi: 10.1016/j.annpat.2017.01.004. Epub 2017 Mar 9. French.

PMID:
28285812
9.

18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis.

Groheux D, Martineau A, Teixeira L, Espié M, de Cremoux P, Bertheau P, Merlet P, Lemarignier C.

Breast Cancer Res. 2017 Jan 5;19(1):3. doi: 10.1186/s13058-016-0793-2.

10.

Droplet Microfluidic and Magnetic Particles Platform for Cancer Typing.

Ferraro D, Champ J, Teste B, Serra M, Malaquin L, Descroix S, de Cremoux P, Viovy JL.

Methods Mol Biol. 2017;1547:113-121. doi: 10.1007/978-1-4939-6734-6_9.

PMID:
28044291
11.

[Backstage of a massive open online course (MOOC) on cancer diagnosis].

Gardair C, Bousquet G, Lehmann-Che J, de Bazelaire C, de Cremoux P, Tran Van Nhieu J, Sockeel M, Battistella M, Calvani J, Gervais J, Pottier Y, Prévaut L, Sekri K, Bertheau P.

Ann Pathol. 2016 Oct;36(5):305-311. doi: 10.1016/j.annpat.2016.08.013. Epub 2016 Sep 14. French.

PMID:
27639771
12.

BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.

Hamy AS, Bieche I, Lehmann-Che J, Scott V, Bertheau P, Guinebretière JM, Matthieu MC, Sigal-Zafrani B, Tembo O, Marty M, Asselain B, Spyratos F, de Cremoux P.

Breast Cancer Res Treat. 2016 Oct;159(3):499-511. doi: 10.1007/s10549-016-3961-2. Epub 2016 Sep 3.

PMID:
27592112
13.

[Academic carriers in oncology and radiotherapy: Explanations for the readers of Bulletin du Cancer].

Soria JC, Bastian G, Bolotine L, Calais G, Céraline J, de Cremoux P, Espié M, Karayan-Tapon L, Laprie A, Mazeron JJ, Négrier S, Roché H.

Bull Cancer. 2016 Sep;103(9):719-29. doi: 10.1016/j.bulcan.2016.07.004. Epub 2016 Aug 23. French. No abstract available.

PMID:
27561824
14.

[Ductal carcinoma in situ diagnosis: 3 French national guidelines].

Cutuli B, Tunon De Lara C, Arnaud A, Bertheau P, Boulanger L, Boute V, Ceugnart L, Chauvet MP, Coutant C, De Cremoux P, Fourquet A, Hennequin C, Lesieur A, Lesur A, Lévy L, Vincent-Salomon A, Besnard S, Belorgey C.

Ann Pathol. 2016 Jun;36(3):166-73. doi: 10.1016/j.annpat.2016.03.012. Epub 2016 May 25. French.

PMID:
27236350
15.

Microfluidic platform combining droplets and magnetic tweezers: application to HER2 expression in cancer diagnosis.

Ferraro D, Champ J, Teste B, Serra M, Malaquin L, Viovy JL, de Cremoux P, Descroix S.

Sci Rep. 2016 May 9;6:25540. doi: 10.1038/srep25540.

16.

¹⁸F-FDG PET/CT for the Early Evaluation of Response to Neoadjuvant Treatment in Triple-Negative Breast Cancer: Influence of the Chemotherapy Regimen.

Groheux D, Biard L, Giacchetti S, Teixeira L, Hindié E, Cuvier C, Vercellino L, Merlet P, de Roquancourt A, de Cremoux P, Resche-Rigon M, Espié M.

J Nucl Med. 2016 Apr;57(4):536-43. doi: 10.2967/jnumed.115.163907. Epub 2015 Dec 23.

17.

[uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].

Luporsi E, Bellocq JP, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Cremoux P, Fina F, Gauchez AS, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V, Kassab-Chahmi D; Institut National du Cancer.

Bull Cancer. 2015 Sep;102(9):719-29. doi: 10.1016/j.bulcan.2015.05.003. Epub 2015 Jul 30. French. No abstract available.

18.

IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients.

Amelot A, De Cremoux P, Quillien V, Polivka M, Adle-Biassette H, Lehmann-Che J, Françoise L, Carpentier AF, George B, Mandonnet E, Froelich S.

PLoS One. 2015 Jul 9;10(7):e0130596. doi: 10.1371/journal.pone.0130596. eCollection 2015.

19.

Early Metabolic Response to Neoadjuvant Treatment: FDG PET/CT Criteria according to Breast Cancer Subtype.

Groheux D, Majdoub M, Sanna A, de Cremoux P, Hindié E, Giacchetti S, Martineau A, de Roquancourt A, Merlet P, Visvikis D, Resche-Rigon M, Hatt M, Espié M.

Radiology. 2015 Nov;277(2):358-71. doi: 10.1148/radiol.2015141638. Epub 2015 Apr 27.

PMID:
25915099
20.

Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.

Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, Espié M, Merlet P, de Roquancourt A, Visvikis D, Hatt M, Resche-Rigon M, Hindié E.

J Nucl Med. 2015 Jun;56(6):824-31. doi: 10.2967/jnumed.115.154138. Epub 2015 Apr 16.

21.

Two cases of non-small-cell lung cancer with rare complex mutation of EGFR exon 18 but different response to targeted therapy.

Gauthier H, Douchet G, Lehmann-Che J, Meignin V, Raynaud C, Sabatier P, de Cremoux H, Poirot B, Culine S, Pouessel D, de Cremoux P.

J Thorac Oncol. 2014 Oct;9(10):e78-9. doi: 10.1097/JTO.0000000000000328. No abstract available.

22.

HDAC inhibition does not induce estrogen receptor in human triple-negative breast cancer cell lines and patient-derived xenografts.

de Cremoux P, Dalvai M, N'Doye O, Moutahir F, Rolland G, Chouchane-Mlik O, Assayag F, Lehmann-Che J, Kraus-Berthie L, Nicolas A, Lockhart BP, Marangoni E, de Thé H, Depil S, Bystricky K, Decaudin D.

Breast Cancer Res Treat. 2015 Jan;149(1):81-9. doi: 10.1007/s10549-014-3233-y. Epub 2014 Dec 12.

PMID:
25503779
23.

[uPA/PAI-1, Oncotype DX™, MammaPrint(®). Prognosis and predictive values for clinical utility in breast cancer management].

Bellocq JP, Luporsi E, Barrière J, Bonastre J, Chetritt J, Le Corroller AG, de Crémoux P, Fina F, Gauchez AS, Kassab-Chahmi D, Lamy PJ, Martin PM, Mazouni C, Peyrat JP, Romieu G, Verdoni L, Mazeau-Woynar V.

Ann Pathol. 2014 Oct;34(5):349-51. doi: 10.1016/j.annpat.2014.04.010. Epub 2014 Aug 22. French.

PMID:
25439987
24.

Concomitant bifocal urothelial carcinoma and breast tumor: second primary cancer or metastatic spread to the breast?

Dumont C, Gauthier H, Vérine J, Lehmann-Che J, de Cremoux P, Pouessel D, Culine S.

Case Rep Oncol Med. 2014;2014:917581. doi: 10.1155/2014/917581. Epub 2014 Aug 4.

25.

Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer.

Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P, de Roquancourt A, de Cremoux P, Marty M, Hatt M, Espié M.

Eur J Cancer. 2014 Jul;50(11):1864-71. doi: 10.1016/j.ejca.2014.04.020. Epub 2014 May 16.

PMID:
24841218
26.

Classification of and risk factors for estrogen deprivation pain syndromes related to aromatase inhibitor treatments in women with breast cancer: a prospective multicenter cohort study.

Laroche F, Coste J, Medkour T, Cottu PH, Pierga JY, Lotz JP, Beerblock K, Tournigand C, Declèves X, de Cremoux P, Bouhassira D, Perrot S.

J Pain. 2014 Mar;15(3):293-303. doi: 10.1016/j.jpain.2013.11.004. Epub 2013 Dec 21.

PMID:
24365325
27.

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.

Beau-Faller M, Prim N, Ruppert AM, Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet JL, Rouquette I, de Crémoux P, Solassol J, de Fraipont F, Bièche I, Cayre A, Favre-Guillevin E, Tomasini P, Wislez M, Besse B, Legrain M, Voegeli AC, Baudrin L, Morin F, Zalcman G, Quoix E, Blons H, Cadranel J.

Ann Oncol. 2014 Jan;25(1):126-31. doi: 10.1093/annonc/mdt418. Epub 2013 Nov 26.

28.

A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platforms.

Beau-Faller M, Blons H, Domerg C, Gajda D, Richard N, Escande F, Solassol J, Denis MG, Cayre A, Nanni-Metellus I, Olschwang S, Lizard S, Piard F, Pretet JL, de Fraipont F, Bièche I, de Cremoux P, Rouquette I, Bringuier PP, Mosser J, Legrain M, Voegeli AC, Saulnier P, Morin F, Pignon JP, Zalcman G, Cadranel J.

J Mol Diagn. 2014 Jan;16(1):45-55. doi: 10.1016/j.jmoldx.2013.07.009. Epub 2013 Oct 30.

29.

Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: experience of the REMAGUS 02 phase II trial.

Valet F, de Cremoux P, Spyratos F, Servant N, Dujaric ME, Gentien D, Lehmann-Che J, Scott V, Sigal-Zafrani B, Mathieu MC, Bertheau P, Guinebretière JM, Pierga JY, Delaloge S, Giacchetti S, Brain E, Tembo O, Marty M, Asselain B.

Breast. 2013 Dec;22(6):1052-9. doi: 10.1016/j.breast.2013.08.015. Epub 2013 Oct 2.

30.

p53 in breast cancer subtypes and new insights into response to chemotherapy.

Bertheau P, Lehmann-Che J, Varna M, Dumay A, Poirot B, Porcher R, Turpin E, Plassa LF, de Roquancourt A, Bourstyn E, de Cremoux P, Janin A, Giacchetti S, Espié M, de Thé H.

Breast. 2013 Aug;22 Suppl 2:S27-9. doi: 10.1016/j.breast.2013.07.005. Review.

31.

Performance and cost efficiency of KRAS mutation testing for metastatic colorectal cancer in routine diagnosis: the MOKAECM study, a nationwide experience.

Blons H, Rouleau E, Charrier N, Chatellier G, Côté JF, Pages JC, de Fraipont F, Boyer JC, Merlio JP, Morel A, Gorisse MC, de Cremoux P, Leroy K, Milano G, Ouafik L, Merlin JL, Le Corre D, Aucouturier P, Sabourin JC, Nowak F, Frebourg T, Emile JF, Durand-Zaleski I, Laurent-Puig P; MOKAECM Collaborative Group.

PLoS One. 2013 Jul 25;8(7):e68945. doi: 10.1371/journal.pone.0068945. Print 2013.

32.

SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases.

Jacquemier J, Spyratos F, Esterni B, Mozziconacci MJ, Antoine M, Arnould L, Lizard S, Bertheau P, Lehmann-Che J, Fournier CB, Krieger S, Bibeau F, Lamy PJ, Chenard MP, Legrain M, Guinebretière JM, Loussouarn D, Macgrogan G, Hostein I, Mathieu MC, Lacroix L, Valent A, Robin YM, Revillion F, Triki ML, Seaume A, Salomon AV, de Cremoux P, Portefaix G, Xerri L, Vacher S, Bièche I, Penault-Llorca F.

BMC Cancer. 2013 Jul 22;13:351. doi: 10.1186/1471-2407-13-351.

33.

Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS 04 trial.

Roca L, Diéras V, Roché H, Lappartient E, Kerbrat P, Cany L, Chieze S, Canon JL, Spielmann M, Penault-Llorca F, Martin AL, Mesleard C, Lemonnier J, de Cremoux P.

Breast Cancer Res Treat. 2013 Jun;139(3):789-800. doi: 10.1007/s10549-013-2587-x. Epub 2013 Jun 19.

PMID:
23780683
34.

Molecular apocrine breast cancers are aggressive estrogen receptor negative tumors overexpressing either HER2 or GCDFP15.

Lehmann-Che J, Hamy AS, Porcher R, Barritault M, Bouhidel F, Habuellelah H, Leman-Detours S, de Roquancourt A, Cahen-Doidy L, Bourstyn E, de Cremoux P, de Bazelaire C, Albiter M, Giacchetti S, Cuvier C, Janin A, Espié M, de Thé H, Bertheau P.

Breast Cancer Res. 2013 May 11;15(3):R37. doi: 10.1186/bcr3421.

35.

Diffusion-weighted MRI in pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer.

Richard R, Thomassin I, Chapellier M, Scemama A, de Cremoux P, Varna M, Giacchetti S, Espié M, de Kerviler E, de Bazelaire C.

Eur Radiol. 2013 Sep;23(9):2420-31. doi: 10.1007/s00330-013-2850-x. Epub 2013 May 8.

PMID:
23652844
36.

Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab.

Cizkova M, Dujaric ME, Lehmann-Che J, Scott V, Tembo O, Asselain B, Pierga JY, Marty M, de Cremoux P, Spyratos F, Bieche I.

Br J Cancer. 2013 May 14;108(9):1807-9. doi: 10.1038/bjc.2013.164. Epub 2013 Apr 23.

37.

Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.

Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M.

Cancer. 2013 Jun 1;119(11):1960-8. doi: 10.1002/cncr.28020. Epub 2013 Mar 15.

38.

Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis.

Akalay I, Janji B, Hasmim M, Noman MZ, André F, De Cremoux P, Bertheau P, Badoual C, Vielh P, Larsen AK, Sabbah M, Tan TZ, Keira JH, Hung NT, Thiery JP, Mami-Chouaib F, Chouaib S.

Cancer Res. 2013 Apr 15;73(8):2418-27. doi: 10.1158/0008-5472.CAN-12-2432. Epub 2013 Feb 22.

39.

Response to "comments on the use of a single or multiple probe-set approach for microarray-based analyses of routine molecular markers in breast cancer".

Spyratos F, Bièche I, de Cremoux P.

Breast Cancer Res Treat. 2013 Jan;137(2):650-1. No abstract available.

PMID:
23413459
40.

Prevalence and distribution of high-risk human papillomavirus genotypes in invasive carcinoma of the uterine cervix in Uruguay.

Berois N, De Cremoux P, Mazal D, Sica A, Cedeira M, Caserta B, Barrios E, Osinaga E, Sastre-Garau X.

Int J Gynecol Cancer. 2013 Mar;23(3):527-32. doi: 10.1097/IGC.0b013e318285e753.

PMID:
23392403
41.

Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts.

Romanelli A, Clark A, Assayag F, Chateau-Joubert S, Poupon MF, Servely JL, Fontaine JJ, Liu X, Spooner E, Goodstal S, de Cremoux P, Bièche I, Decaudin D, Marangoni E.

Mol Cancer Ther. 2012 Dec;11(12):2693-703. doi: 10.1158/1535-7163.MCT-12-0441-T. Epub 2012 Sep 25.

42.

Concurrent use of aromatase inhibitors and hypofractionated radiation therapy.

Chargari C, Castro-Pena P, Toledano I, Bollet MA, Savignoni A, Cottu P, Laki F, Campana F, De Cremoux P, Fourquet A, Kirova YM.

World J Radiol. 2012 Jul 28;4(7):318-23. doi: 10.4329/wjr.v4.i7.318.

43.

[Cell signalling and cancer: characterisation of therapeutic targets].

de Cremoux P, Robert J.

Pathol Biol (Paris). 2012 Aug;60(4):217-22. doi: 10.1016/j.patbio.2012.05.006. Epub 2012 Jun 22. Review. French.

PMID:
22728008
44.

Comments on the use of a single or multiple probeset approach for microarray-based analyses of routine molecular markers in breast cancer.

Spyratos F, Valet F, Bièche I, Scott V, Lehmann-Che J, Asselain B, Tembo O, Marty M, de Cremoux P.

Breast Cancer Res Treat. 2012 Jul;134(1):443-8. doi: 10.1007/s10549-012-2042-4. Epub 2012 Apr 12. No abstract available.

PMID:
22527097
45.

Three different KRAS statuses in three synchronous colorectal cancers.

Jolissaint L, Cacheux W, Mariani P, Le Tourneau C, Lièvre A, Lappartient E, Margogne A, Farkhondeh F, de Cremoux P.

Med Oncol. 2012 Dec;29(4):2864-5. doi: 10.1007/s12032-012-0214-z. Epub 2012 Apr 1.

PMID:
22467075
46.

Molecular profiling of patient-derived breast cancer xenografts.

Reyal F, Guyader C, Decraene C, Lucchesi C, Auger N, Assayag F, De Plater L, Gentien D, Poupon MF, Cottu P, De Cremoux P, Gestraud P, Vincent-Salomon A, Fontaine JJ, Roman-Roman S, Delattre O, Decaudin D, Marangoni E.

Breast Cancer Res. 2012 Jan 16;14(1):R11.

47.

Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.

Luporsi E, André F, Spyratos F, Martin PM, Jacquemier J, Penault-Llorca F, Tubiana-Mathieu N, Sigal-Zafrani B, Arnould L, Gompel A, Egele C, Poulet B, Clough KB, Crouet H, Fourquet A, Lefranc JP, Mathelin C, Rouyer N, Serin D, Spielmann M, Haugh M, Chenard MP, Brain E, de Cremoux P, Bellocq JP.

Breast Cancer Res Treat. 2012 Apr;132(3):895-915. doi: 10.1007/s10549-011-1837-z. Epub 2011 Nov 3. Review.

48.

[Hormone therapy and breast cancer].

de Cremoux P.

Bull Cancer. 2011 Nov;98(11):1311-9. doi: 10.1684/bdc.2011.1466. Review. French.

49.

Modeling of response to endocrine therapy in a panel of human luminal breast cancer xenografts.

Cottu P, Marangoni E, Assayag F, de Cremoux P, Vincent-Salomon A, Guyader Ch, de Plater L, Elbaz C, Karboul N, Fontaine JJ, Chateau-Joubert S, Boudou-Rouquette P, Alran S, Dangles-Marie V, Gentien D, Poupon MF, Decaudin D.

Breast Cancer Res Treat. 2012 Jun;133(2):595-606. doi: 10.1007/s10549-011-1815-5. Epub 2011 Oct 16.

PMID:
22002565
50.

A critical view of the effects of phytoestrogens on hot flashes and breast cancer risk.

This P, de Cremoux P, Leclercq G, Jacquot Y.

Maturitas. 2011 Nov;70(3):222-6. doi: 10.1016/j.maturitas.2011.07.001. Epub 2011 Aug 2. Review.

PMID:
21813250

Supplemental Content

Loading ...
Support Center